

For the use only of a Registered Medical Practitioner or a Hospital or a Laboratory
---

This package insert is continually updated: Please read carefully before using a new pack
---

## **Belumosudil Tablets 200mg REZUROCK®**

### **1. Generic Name**

Belumosudil Tablets 200mg

### **2. Qualitative and quantitative composition**

Each film-coated tablet contains 200 mg belumosudil (equivalent to 242.5 mg belumosudil mesylate). Excipients (per 200 mg tablet):

Tablet core: microcrystalline cellulose (219 mg), hypromellose (25 mg), croscarmellose sodium (10 mg), colloidal silicon dioxide (1 mg), and magnesium stearate (2.5 mg).

Coating Composition: polyvinyl alcohol, polyethylene glycol, talc, titanium dioxide and yellow iron oxide.

### **3. Dosage form and strength**

Each 200 mg tablet is a pale-yellow film-coated oblong tablet.

### **4. Clinical particulars**

#### **4.1 Therapeutic indication**

Belumosudil is indicated for the treatment of patients 12 years and older with chronic graft-versus-host disease (chronic GvHD) after failure of at least two prior lines of systemic therapy.

#### **4.2 Posology and method of administration General**

The recommended dose of belumosudil is 200 mg given orally once daily.

##### *Dose Modifications*

The recommended belumosudil dosage modifications in case of adverse reactions are provided below.

**Table 1 - Recommended Dosage Modifications for Belumosudil for Adverse Reactions**

<b>Adverse Reaction</b>	<b>Severity*</b>	<b>Belumosudil Dose Modification</b>
<b>Hepatotoxicity (see Section Adverse Reactions)</b>	Grade 3 ALT or AST ( $>5$ to $20 \times$ ULN) or Grade 2 bilirubin ( $>1.5$ to $3 \times$ ULN)	Hold belumosudil until recovery to $\leq$ Grade 1, then resume belumosudil recommended dose.
	Grade 4 ALT or AST ( $>20 \times$ ULN) or Grade $\geq 3$ bilirubin ( $>3 \times$ ULN)	Permanently discontinue belumosudil.
<b>Other adverse reactions (see Section Adverse Reactions)</b>	Grade 3	Hold belumosudil until recovery to $\leq$ Grade 1, then resume belumosudil at the recommended dose level.
	Grade 4	Permanently discontinue belumosudil.

\*Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03

#### *Dosage Modification Due to Drug Interactions*

##### Strong CYP3A Inducers

Increase the dosage of belumosudil to 200 mg twice daily when co-administered with strong CYP3A inducers (see Section Interactions).

##### Proton Pump Inhibitors

Increase the dosage of belumosudil to 200 mg twice daily when co-administered with proton pump inhibitors (see Section Interactions).

#### **SPECIAL POPULATIONS**

##### Pediatric patients

The safety and effectiveness of belumosudil tablets in pediatric patients aged less than 12 years have not been established.

##### Elderly patients

No dose adjustment is recommended over the age of 65 years. Of the 186 patients with chronic GvHD in clinical studies of belumosudil, 25.8% were 65 years and older. No overall differences in safety or effectiveness of belumosudil were observed between these patients and younger patients (see Section Pharmacokinetic properties).

##### Hepatic impairment

Use in patients with moderate hepatic impairment (Child-Pugh B) or severe hepatic impairment (Child-Pugh C) without liver GVHD is not recommended (see Section Pharmacokinetic Properties). No dose adjustment is recommended when administering belumosudil to patients with mild hepatic impairment (Child-Pugh A) (see Section Pharmacokinetic properties).

Monitor patients frequently for adverse reactions.

#### Renal impairment

No dose adjustment is recommended in patients with mild or moderate renal impairment. The effect of severe renal impairment has not been evaluated (see Section Pharmacokinetic properties).

#### **Administration**

Belumosudil tablets should be taken orally once daily at approximately the same time each day with a meal.

If the patient misses a dose of belumosudil, instruct the patient not to take extra doses to make up the missed dose.

### **4.3 Contraindications**

Belumosudil is contraindicated in patients who are hypersensitive to this drug or to any ingredient in the formulation.

### **4.4 Special warnings and precautions for use**

#### Embryo-Fetal Toxicity

Based on findings in animals and its mechanism of action, belumosudil can cause fetal harm when administered to a pregnant woman. In animal reproduction studies, administration of belumosudil to pregnant rats and rabbits during the period of organogenesis caused adverse developmental outcomes including embryo- fetal mortality and malformations at maternal exposures (AUC) less than those in patients at the recommended dose.

Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential and males with female partners of reproductive potential to use effective contraception during treatment with belumosudil and for at least one week after the last dose of belumosudil (see Section Pregnancy and Non clinical properties).

### **4.5 Drugs interactions**

#### **Effect of other drugs on belumosudil**

#### Strong CYP3A4 Inducers

Coadministration of belumosudil with strong CYP3A inducers decreases belumosudil exposure, (see Section Pharmacological properties) which may reduce the efficacy of belumosudil. Increase the dosage of belumosudil when co-administered with strong CYP3A inducers (see Section Posology and Method of administration).

#### Proton Pump Inhibitors

Coadministration of belumosudil with proton pump inhibitors decreases belumosudil exposure, (see Section Pharmacological properties) which may reduce the efficacy of belumosudil. Increase the dosage of belumosudil when co-administered with proton pump inhibitors (see Section Posology and Method of administration).

## **Effect of belumosudil on other drugs**

### *Certain UGT1A1 substrates*

Avoid coadministration of belumosudil with UGT1A1 substrates for which minimal concentration changes may lead to serious toxicities. If coadministration cannot be avoided, decrease the UGT1A1 substrates dosage(s) in accordance with the respective Prescribing Information.

Belumosudil is an inhibitor of UGT1A1. Coadministration of belumosudil with a UGT1A1 substrate decreased plasma concentrations of the glucuronide metabolite (see Section Pharmacokinetic Properties), which may increase the risk of adverse reactions related to sensitive substrates of UGT1A1.

### *Certain P-gp, OATP1B1, and BCRP substrates*

Avoid coadministration of belumosudil with P-gp (e.g. dabigatran), OATP1B1, and BCRP substrates (e.g. rosuvastatin), for which minimal concentration changes may lead to serious toxicities. If coadministration cannot be avoided, decrease the P-gp, OATP1B1, and BCRP substrates dosage(s) in accordance with the respective Prescribing Information.

Belumosudil is an inhibitor of P-gp, OATP1B1, and BCRP. Coadministration of belumosudil with P-gp, OATP1B1, and BCRP substrates increased their plasma concentrations (see Section Pharmacokinetic Properties), which may increase the risk of adverse reactions related to these substrates.

### *Certain CYP1A2 substrates*

Avoid coadministration of belumosudil with sensitive CYP1A2 substrates, for which minimal concentration changes may lead to serious toxicities. If coadministration cannot be avoided, decrease the CYP1A2 substrate dosage(s) in accordance with the respective Prescribing Information.

Coadministration of belumosudil with sensitive CYP1A2 substrates (e.g. caffeine) is predicted to increase CYP1A2 substrate exposure (see Section Pharmacokinetic Properties).

### *Drug-Food Interactions*

In healthy subjects, the administration of a single 200 mg dose of belumosudil with a high-fat and high-calorie meal (800 to 1,000 calories with approximately 50% of total caloric content of the meal from fat) increased  $C_{\max}$  to 2.2 times that following fasted administration and AUC to 2 times that following fasted administration. Median  $T_{\max}$  was delayed 0.5 hours.

## **4.6 Use in special populations (such as pregnant women, lactating women, paediatric patients, geriatric patients etc.)**

### **Pregnancy**

Verify the pregnancy status of females of reproductive potential prior to initiating treatment with belumosudil.

Based on findings from animal studies and the mechanism of action, (see Section Reproductive and Developmental Toxicity) belumosudil can cause fetal harm when administered to pregnant women. There are no available data on belumosudil use in pregnant women.

No conclusions can be drawn regarding whether or not belumosudil is safe for use during pregnancy. The use of belumosudil in pregnant women is not recommended.

### Contraception

#### Females

Advise females of reproductive potential to use effective contraception during treatment with belumosudil and for at least one week after the last dose of belumosudil. If this drug is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be informed of the potential hazard to a fetus.

#### Males

Advise male patients with female partners of reproductive potential to use effective contraception during treatment with belumosudil and for at least one week after the last dose of belumosudil.

### **Lactation**

No human or animal data are available to assess the impact of belumosudil on milk production, its presence in breast milk, or its effects on the breastfed infant. No conclusions can be drawn regarding whether belumosudil is safe for use during breastfeeding. Breastfeeding is not recommended during treatment with belumosudil and for at least one week after the last dose.

### **Fertility**

No human data are available to determine potential effects of belumosudil on fertility in females and males.

Belumosudil repeat dose toxicity studies in rats demonstrated effects of general toxicity manifesting low body weight that may lead to impairment of female fertility (see Section Nonclinical Properties).

Based on testicular findings from rats and dogs, belumosudil may impair male fertility (see Section Nonclinical Properties).

Refer to section 4.2 for Special Populations.

## **4.7 Effects on ability to drive and use machines**

Belumosudil has no influence on the ability to drive and use machines. The clinical status and adverse reactions experienced by the patient should be considered when assessing the patient's ability to perform tasks that require judgement, motor, or cognitive skills.

## **4.8 Undesirable effects**

### **ADVERSE REACTIONS**

The following CIOMS frequency rating is used, when applicable:

Very common  $\geq 10\%$ ; Common  $\geq 1$  and  $< 10\%$ ; Uncommon  $\geq 0.1$  and  $< 1\%$

Rare  $\geq 0.01$  and  $< 0.1\%$ ; Very rare  $< 0.01\%$ ; Unknown (cannot be estimated from available data).

## CLINICAL TRIALS

### *Clinical Trial Study Data*

In two open-label clinical trials (Study KD025-213 and Study KD025-208), 83 adult patients with chronic GvHD were treated with belumosudil 200 mg once daily (see Section Clinical Efficacy). As of 19 February 2020, the median follow-up time was 9.2 months, and the median duration of treatment was 6.9 months (range 0.5 to 38.7 months).

As of 19 February 2020, the most commonly occurring adverse reactions in the patients with chronic GvHD treated with 200 mg once daily belumosudil in clinical trials ( $\geq 20\%$ ) were fatigue, diarrhea, upper respiratory tract infection, nausea, dyspnea, cough, peripheral edema, and vomiting. The most common Grade 3 or 4 adverse reactions ( $\geq 5\%$ ) were pneumonia (7.2%), hyperglycemia (6.0%), and hypertension (6.0%).

The most frequent reasons for discontinuation were progression of chronic GvHD (13%) and recurrence of the underlying malignancy (8%) in patients with chronic GvHD treated with 200 mg once daily. Most common other adverse reactions leading to discontinuation were nausea (2.4%) and headache (2.4%). Adverse reactions leading to dose interruption occurred in 28.9% of patients were mainly infections (14.5%) including pneumonia (6.0%). Other adverse reactions ( $\geq 2\%$ ) leading to dose interruption were diarrhea (3.6%), hypotension (2.4%), vomiting (2.4%), and pyrexia (2.4%). The most commonly reported TEAEs ( $\geq 10\%$  of belumosudil-treated subjects) are summarized by SOC and PT for subjects with chronic GvHD in Table 2.

**Table 2 – Most Common ( $\geq 10\%$ ) Treatment-Emergent Adverse Events by System Organ Class and Preferred Term (Safety Population)**

Adverse Reaction	Belumosudil 200 mg once daily (N=83)	
	All Grades <sup>a</sup> (%)	Grade 3-4 <sup>a</sup> (%)
<b>Blood and lymphatic system disorders</b>		
<b>Anemia</b>	12.0	4.8
<b>Gastrointestinal disorders</b>		
<b>Diarrhea</b>	32.5	3.6
<b>Nausea</b>	28.9	2.4
<b>Vomiting</b>	21.7	2.4
<b>Dysphagia</b>	15.7	0
<b>Abdominal pain</b>	12.0	1.2
<b>General disorders and administration site conditions</b>		
<b>Fatigue</b>	39.8	1.2

Adverse Reaction	Belumosudil 200 mg once daily (N=83)	
	All Grades <sup>a</sup> (%)	Grade 3-4 <sup>a</sup> (%)
Edema peripheral	24.1	1.2
Pyrexia	16.9	1.2
<b>Infections and infestations</b>		
Upper respiratory tract infection	30.1	0
Pneumonia	10.8	7.2
<b>Injury, poisoning and procedural complications</b>		
Contusion	12.0	0
<b>Investigations</b>		
Alanine aminotransferase increased	12.0	1.2
Aspartate aminotransferase increased	12.0	1.2
Gamma-Glutamyl transferase increased	10.8	4.8
<b>Metabolism and nutrition disorders</b>		
Decreased appetite	14.5	1.2
Hyperglycemia	13.3	6.0
<b>Musculoskeletal and connective tissue disorders</b>		
Muscle spasm	15.7	0
Arthralgia	13.3	2.4
<b>Nervous system disorders</b>		
Headache	18.1	0
<b>Respiratory, thoracic and mediastinal disorders</b>		
Dyspnea	26.5	3.6
Cough	24.1	0
Nasal congestion	12.0	0
Productive cough	10.8	0
<b>Vascular disorders</b>		
Hypertension	19.3	6.0
<sup>a</sup> National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), version 5.0 and version 4.03.		

### Description of Selected Laboratory Abnormalities

Table 3 below displays shifts in Common Terminology Criteria (CTC) grade from baseline to maximum post- baseline for safety population, analysis group 1 in KD-025 Integrated Summary of Safety (ISS) for 83 patients in chronic GvHD studies (KD025-208 and KD025-213) who received belumosudil 200 mg once daily.

**Table 3- Selected Laboratory Abnormalities Worsening from Baseline in Patients with cGvHD Who Received Belumosudil**

	<b>BELUMOSUDIL 200 mg once daily (N=83)</b>		
	<b>Grade 0-1 Baseline</b>	<b>Grade 2-4 Max Post</b>	<b>Grade 3-4 Max Post</b>
<b>Parameter</b>	<b>N</b>	<b>%</b>	<b>%</b>
<b>Chemistry</b>			
<b>Phosphate Decreased</b>	76	28	7
<b>Gamma Glutamyl Transferase Increased</b>	47	21	11
<b>Calcium Decreased</b>	82	12	1
<b>Alkaline Phosphatase Increased</b>	80	9	0
<b>Potassium Increased</b>	82	7	1
<b>Alanine Aminotransferase Increased</b>	83	7	2
<b>Creatinine Increased</b>	83	4	0
<b>Hematology</b>			
<b>Lymphocytes Decreased</b>	62	29	13
<b>Hemoglobin Decreased</b>	79	11	1
<b>Platelets Decreased</b>	82	10	5
<b>Neutrophil Count Decreased<sup>a</sup></b>	17	0	0
<sup>a</sup> Neutrophil data for KD025-208 study only.			



## 4.9 Overdose

There is no specific experience in the management of belumosudil overdose in patients. There is no known antidote for overdoses with belumosudil. Single doses up to 1000 mg have been given with acceptable tolerability in healthy volunteers. In the event of an overdose, undertake all appropriate supportive measures immediately.

## 5. Pharmacological properties

### 5.1 Mechanism of Action

Belumosudil is an inhibitor of Rho-associated, coiled-coil containing protein kinase (ROCK) which inhibits ROCK2 and ROCK1 with IC<sub>50</sub> values of approximately 100 nM and 3 µM, respectively. Belumosudil down-regulated proinflammatory responses via regulation of STAT3/STAT5 phosphorylation and shifting Th17/Treg balance in ex-vivo or *in vitro*-human T cell assays. Belumosudil also inhibited aberrant pro-fibrotic signaling, *in vitro*. *In vivo*, belumosudil demonstrated activity in animal models of chronic GvHD.

### 5.2 Pharmacodynamic properties

#### Cardiac Electrophysiology

At a dose of 5 times the recommended dose, belumosudil does not prolong the QT interval to any clinically relevant extent.

### 5.3 Pharmacokinetic properties

The following pharmacokinetic parameters are presented for chronic GvHD patients administered belumosudil 200 mg once daily, unless otherwise specified. The mean (% coefficient of variation, %CV) steady-state AUC and C<sub>max</sub> of belumosudil were 22,700 (48%) h\*ng/mL and 2390 (44%) ng/mL, respectively. Belumosudil C<sub>max</sub> and AUC increased in an approximately proportional manner over a dosage range of 200 and 400 mg (1 to 2 times once daily recommended dosage). The accumulation ratio of belumosudil was 1.35.

#### Absorption

Median T<sub>max</sub> of belumosudil at steady state was 1.98 to 2.53 hours following administration of 200 mg once daily in patients. The mean (%CV) bioavailability was 63.7% (17.3%) following a single belumosudil dose in healthy subjects.

#### Effect of Food

In healthy subjects, the administration of a single 200 mg dose of belumosudil with a high-fat and high-calorie meal (800 to 1,000 calories with approximately 50% of total caloric content of the meal from fat) increased belumosudil C<sub>max</sub> to 2.2 times that following fasted administration and AUC to 2 times that following fasted administration. Median T<sub>max</sub> was delayed 0.5 hour.

#### Distribution

The geometric mean volume of distribution after a single dose of belumosudil in healthy subjects was 184 L (geo CV% 67.7%).

Belumosudil binding to human serum albumin and human  $\alpha$ 1-acid glycoprotein was 99.9% and 98.6%, respectively, *in vitro*.

#### Metabolism

Belumosudil is primarily metabolized by CYP3A4 and to a lesser extent by CYP2C8, CYP2D6, and UGT1A9, *in vitro*.

#### Excretion

Following a single oral dose of radiolabeled belumosudil, in healthy subjects, 85% of radioactivity was recovered in feces (30% as unchanged) and less than 5% was recovered in urine.

#### Elimination

Belumosudil elimination half-life in patients (% coefficient of variation [CV]) was 19.0 h (39%). Belumosudil clearance in patients (%CV) was 9.83 L/h (46%).

#### Special populations

##### Gender

Based on population PK analysis, there was no significant effects of sex on pharmacokinetics of belumosudil.

##### Race

Based on population PK analysis, there was no significant effects of race on pharmacokinetics of belumosudil.

##### Elderly

Age is not expected to affect the pharmacokinetics of belumosudil, based on clinical data.

##### Pediatric

Belumosudil pharmacokinetic have not been studied in pediatric population below 12 years of age.

##### Hepatic Impairment

Following a single 200 mg dose of belumosudil, changes in belumosudil exposure in subjects with varying degrees of hepatic impairment based on Child-Pugh score without liver GVHD relative to subjects with normal hepatic function is shown in Table 4.

**Table 4: Effect of Varying Degrees of Hepatic Impairment on Belumosudil Exposure**

Hepatic Impairment Category	Changes in Belumosudil Exposure in Subjects with Hepatic Impairment Compared to Subjects with Normal Hepatic Function			
	Total (Free + Bound) Concentrations		Free Concentrations	
	C <sub>max</sub>	AUC	C <sub>max</sub>	AUC
Mild (Child-Pugh A)	1.2-fold increase	1.4-fold increase	14% decrease	19% decrease
Moderate (Child-Pugh B)	6% decrease	1.5-fold increase	12% decrease	1.4-fold increase
Severe (Child-Pugh C)	1.3-fold increase	4.2-fold increase	5.4-fold increase	16-fold increase

### Renal Impairment

Belumosudil pharmacokinetics are not affected by mild to moderate renal impairment. The effect of severe renal impairment on belumosudil pharmacokinetics has not been studied.

### Drug Interaction Studies

#### *Clinical Studies and Model-Informed Approaches Effects of Other Drugs on Belumosudil*

Strong Cytochrome P450 (CYP) 3A Inhibitors: There was no clinically meaningful effect on belumosudil exposure when co-administered with itraconazole in healthy subjects.

Strong CYP3A4 Inducers: Coadministration of rifampin decreased belumosudil C<sub>max</sub> by 59% and AUC by 72% in healthy subjects.

Moderate CYP3A Inducers: Coadministration of efavirenz is predicted to decrease belumosudil C<sub>max</sub> by 19% and AUC by 35% in healthy subjects.

Proton Pump Inhibitors: Coadministration of rabeprazole decreased belumosudil C<sub>max</sub> by 87% and AUC by 80%, and coadministration of omeprazole decreased belumosudil C<sub>max</sub> by 68% and AUC by 47% in healthy subjects.

#### *Effects of Belumosudil on Other Drugs*

#### *Enzyme systems*

CYP1A2 substrates: Coadministration of belumosudil is predicted to increase caffeine (a sensitive CYP1A2 substrate) C<sub>max</sub> and AUC approximately 1.08- and 1.59-fold, respectively.

CYP3A Substrates: Coadministration of belumosudil is predicted to increase midazolam (a sensitive CYP3A substrate)  $C_{\max}$  and AUC approximately 1.26- and 1.47-fold, respectively.

CYP2C9 Substrates: Coadministration of belumosudil is not expected to have clinically meaningful effect on the exposure of CYP2C9 substrates (such as warfarin).

CYP2C8 Substrates: Coadministration of belumosudil is not expected to have clinically meaningful effect on the exposure of CYP2C8 substrates that are not an OATP1B1 substrate.

UGT1A1 Substrates: Coadministration of belumosudil decreased raltegravir glucuronide (metabolite formed via the UGT1A1 pathway)  $C_{\max}$  by 42% and AUC by 40%.

#### *Transporter systems*

*OATP1B1/BCRP substrates:* Coadministration of belumosudil increases rosuvastatin  $C_{\max}$  and AUC by 3.6 and 4.6-fold, respectively (see Section Interactions).

P-glycoprotein (P-gp) substrates: Coadministration of belumosudil increased the exposure of dabigatran by 2- fold.

#### *In Vitro Studies*

*Enzymes Systems:* Belumosudil is an inhibitor of CYP1A2, CYP2C19, CYP2D6, UGT1A1 and UGT1A9.

*Transporter Systems:* Belumosudil is a substrate of P-glycoprotein (P-gp). Belumosudil inhibits BCRP, P-gp, and OATP1B1 at clinically relevant concentrations.

## **5.4 Clinical Efficacy**

### **Chronic Graft versus Host Disease**

Two open-label Phase 2 studies (studies KD025-213 and KD025-208) were conducted in patients with chronic GvHD. In both studies, the primary efficacy endpoint was the overall response rate (ORR), defined as the proportion of subjects who achieved a complete response (CR) or a partial response (PR) according to the 2014 NIH Consensus Development Project on Criteria for Clinical Trials in chronic GvHD.

Study KD025-208 (N=54) was a dose-escalation, open-label, multicenter study of belumosudil for treatment of patients with chronic GvHD who had received 1 to 3 prior lines of systemic therapy and required additional therapy. Initiation of one or more new systemic therapies for chronic GvHD indicates a new line of therapy. Belumosudil was administered orally at 200 mg once daily (n=17), 200 mg twice daily (n=16), or 400 mg once daily (n=21). Concomitant treatment of chronic GvHD with corticosteroids and calcineurin inhibitors was permitted.

Study KD025-213 (N=132) was a randomized, open-label, multicenter study of belumosudil for treatment of patients with chronic GvHD who had received 2 to 5 prior lines of systemic therapy and required additional treatment. There were 66 patients treated with belumosudil 200 mg taken orally once daily, the other 66 patients received belumosudil 200 mg BID. Concomitant treatment with supportive care therapies for chronic GvHD was permitted. Concomitant treatment with GvHD prophylaxis and standard care systemic chronic GvHD therapies was permitted as long as the subject has been on a stable dose for at least 2 weeks prior to study. Initiation of new systemic chronic GvHD therapy while on study was not permitted.

Efficacy results are summarized in Table 5.

**Table 5 - Best Overall Response Rate (ORR) and Other Efficacy Results in chronic GvHD Study**

	<b>KD025-213 (2-5 prior lines excluding subject 105- 104) 200 mg once daily (N=65)</b>
Overall Response Rate (%) <sup>a</sup>	49 (75%) <sup>b</sup>
95% CI	(63.1, 85.2)
K-M Duration of Response, Median, Months, 95% CI (Based on responder population)	1.9 (1.2, 2.9) <sup>d</sup>
≥7 Point Decrease in Lee Symptom Scale Score on Consecutive Assessments, n (%)	34 (52.3)

CI = Confidence Interval; K-M = Kaplan Meier; NR = Not Reached;

KARA = Kadmon Algorithmic Response Assessment

a Responses assessed by investigators based on the 2014 NIH Response Criteria

b ORR is defined as the proportion of patients with best ORR of CR or PR through Cycle 7 Day 1

d This responder population is defined based on response status of KARA. Duration of response is defined as the time from first ORR response to progression of disease in any organ measure in comparison to nadir, new systemic therapy, or death, whichever comes first.

In study KD025-213, complete response (CR) was achieved in 4 patients along with partial response (PR) being achieved in majority of patients through Cycle 7 Day 1. The median time to response through Cycle 7 Day 1 was 1.8 months (range, 0.9 to 5.6months). In patients who achieved response (N=49), no death or new systemic therapy initiation occurred in 65% (95% CI: 0.49, 0.77) of patients for at least 12 months since response.

## 6. Nonclinical properties

### 6.1 Animal Toxicology or Pharmacology

#### Repeat Dose toxicity

Repeated oral dose studies with belumosudil of up to 6-month in rats and 3 -month in the dog were conducted.

The exposure ratio shows the fold difference between animal exposure at NOAEL and human exposure at human recommended dose at 200 mg once daily (see Table 6).

**Table 6 - Summary of animal/human exposure ratios after repeated administration in the rodent and non-rodent toxicological studies**

Species	Type	Study Duration	Recovery	Gender	Doses tested (mg/kg/day)	Exposure ratio QD
Rat		6 Months	4 weeks	M	<50 <sup>a</sup> ; 125; 275	<1.1 <sup>a</sup>
		6 Months	4 weeks	F	50; 125; 275	7.4 <sup>a</sup>
Dog	Toxicology	3 Months	4 weeks	M	<35 <sup>b</sup> ; 70; 125	<1.1
			4 weeks	F	35; 70; 125	1.0

<sup>a</sup> Exposure ratio presented based upon 6-month toxicokinetic exposure data.

<sup>b</sup> no-observed-adverse-effect level (NOAEL) in bold

Abbreviations: QD = once daily; F = female; M = male; NA = Not Applicable

Following administration of belumosudil to rats and/or dogs, the adverse effects observed in one or both species included toxicities in the gastrointestinal (GI) tract (emesis, loose stools, and/or abnormal black contents, increase in salivation), liver (elevated liver enzymes, hypertrophy/increased organ weight, and cholestasis/inflammation), kidney (increased blood urea nitrogen [BUN], tubular changes, pigmentation, intracellular protein droplets in the epithelium), hemolymphoid system (regenerative anemia), and reproductive system. The reproductive system toxicity involved both the male and female reproductive organs and associated tissues. In females, changes included lower uterine weights that correlated with uterine/cervical hypoplasia and decreased follicular development in rats at 275 mg/kg/day related to adverse body weight reduction due to lower food consumption and would lead to functional impairment of fertility; findings were reversible. In males, toxicities included lower epididymis and testes weights associated with multifocal bilateral spermatozoan degeneration in the epididymis and testes, and multinucleated spermatids in the testes in the repeat dose studies, and the changes were reversible in dogs but not fully reversible in rats.

#### Genotoxicity

Belumosudil was not genotoxic in an *in vitro* bacterial mutagenicity (Ames) assay, *in vitro* chromosome aberration assay in human peripheral blood lymphocytes (HPBL) or an *in vivo* rat bone marrow micronucleus assay.

## **Carcinogenicity**

Belumosudil did not result in any carcinogenic effect in a 6-month CByB6F1-Tg (HRAS)<sup>2Jic</sup> hemizygous mouse study.

## **Reproductive and Developmental Toxicity**

In a male and female rat fertility study and early embryonic development, belumosudil-treated male animals were mated with untreated females, or untreated males were mated with belumosudil-treated females. Belumosudil was administered orally at doses of 50, 150 or 275 mg/kg/day to male rats 70 days prior to and throughout the mating period, and to female rats 14 days prior to mating and up to Gestation Day 7. At the dose of 275 mg/kg/day, adverse findings in female rats (treated with belumosudil or untreated but mated with treated males) regarding early embryonic development included increased pre- or post-implantation loss and decreased number of viable embryos. Administration of belumosudil to male rats at a dose of 275 mg/kg/day resulted in abnormal sperm findings (reduced motility, reduced count, and increased percentage of abnormal sperm), and testes/epididymis organ changes (reduced weight and degeneration). Fertility was reduced in treated males but not in treated females at the 275 mg/kg/day dose.

Adverse changes in male and female reproductive organs also occurred in general 3-month and 6 month toxicology studies. In males, findings included spermatozoa degeneration at a belumosudil dose of 50 mg/kg/day in rats and 35 mg/kg/day in dogs. The exposure (AUC) at the doses of 50 mg/kg/day in male rats and 35 mg/kg/day in male dogs is 1.1-fold the clinical exposure at the recommended human dose of 200 mg/day. Changes were reversible in dogs but not fully reversible in rats. In female, rats, changes included lower uterine weights that correlated with uterine/cervical hypoplasia and decreased follicular development in ovaries related to adverse body weight reduction due to lower food consumption at 275 mg/kg/day [corresponding to 9-fold exposure in patients at the recommended human dose of 200 mg/day]. Changes were fully reversed during the 4-week recovery period.

Embryo-fetal development studies were conducted in rats with administration of belumosudil to pregnant animals during the period of organogenesis at oral doses of 25, 50, 150, and 300 mg/kg/day in an exploratory study and doses of 15, 50, and 150 mg/kg/day in a pivotal study. In the exploratory study, maternal toxicity and embryo- fetal developmental effects were observed. Maternal toxicity (reduced body weight gain) occurred at 150 and 300 mg/kg/day doses. Increased post-implantation loss occurred at 50 and 300 mg/kg/day. Fetal malformations were observed at  $\geq 50$  mg/kg/day and included absence of anus and tail, omphalocele, and dome shaped head. The exposure (AUC) at 50 mg/kg/day in rats is approximately 1.4-fold the human exposure at the recommended dose of 200 mg daily.

In an embryo-fetal developmental study in rabbits, pregnant animals administered oral doses of belumosudil at 50, 125, and 225 mg/kg/day during the period of organogenesis resulted in maternal toxicity and embryo- fetal developmental effects. Maternal toxicity (body weight loss and mortality) was observed at doses  $\geq 125$  mg/kg/day. Embryo-fetal effects were observed at doses  $\geq 50$  mg/kg/day and included spontaneous abortion, increased post-implantation loss, decreased percentage of live fetuses, malformations, and decreased fetal body weight. Malformations included those in the tail (short), ribs (branched, fused or deformed), sternbrae (fused), and neural arches (fused, misaligned, and deformed). The exposure (AUC) at 50 mg/kg/day in rabbits is approximately 0.08-fold the human exposure at the recommended dose of 200 mg daily.

## Other Toxicity Studies


### Phototoxicity

*In-vitro* belumosudil has demonstrated photo-absorbance between 290 and 370 nm and positive phototoxic potential in the *in vitro* 3T3 Neutral Red Uptake Assay. No phototoxicity studies have been performed in animals. Based on standard reporting of adverse events in phase 1/2, belumosudil has not demonstrated any clinically significant ocular phototoxicity or skin related adverse events in patients.

## 7. Description

### Active Moiety(ies) / Active Ingredients

Belumosudil mesylate is a kinase inhibitor. The active pharmaceutical ingredient is belumosudil mesylate with the molecular formula  $C_{27}H_{28}N_6O_5S$  and the molecular weight is 548.62 g/mol. The chemical name is 2-{3-[4- (1*H*-indazol-5-ylamino)-2-quinazolinyl]phenoxy}-*N*-(propan-2-yl)acetamide methanesulfonate (1:1). The chemical structure is as follows:



Belumosudil mesylate is a yellow crystalline solid. It is soluble in dimethylsulfoxide (DMSO), slightly soluble in dimethylformamide (DMF) and methanol, very slightly soluble in 2.0 pH (PBS buffer), and practically insoluble in water, acetonitrile, toluene, ethyl acetate, dichloromethane (DCM), acetone, isopropyl alcohol, *n*- heptane and in solutions at pH 2.0, 4.5, and 6.8 (PBS buffers).

### Therapeutic or Pharmacological Class

Pharmacotherapeutic group: Antineoplastic and immunomodulating agents.

ATC code: L04AA48 belumosudil

Pharmacological Class: Belumosudil is a Rho-associated, coiled-coil containing protein kinase-2 (ROCK2) selective kinase inhibitor.

## 8. Pharmaceutical particulars

### 8.1 Incompatibilities

No information

### 8.2 Shelf-life

Shelf Life: 36 months.

### 8.3 Packaging information

200 mg tablets: 30 counts in 60 cc high-density polyethylene (HDPE) bottle with a desiccant.



#### **8.4 Storage and handling instructions**

Store at room temperature, 20°C to 25°C (68°F to 77°F); excursions permitted from 15°C and 30°C (59°F to 86°F) [Refer to local dossier]. Dispense to patient in original container only. Store in original container to protect from moisture. Replace cap securely each time after opening. Do not discard desiccant.

### **9 Patient Counselling Information**

#### *What is Belumosudil used for?*

Belumosudil is a prescription medicine used to treat adults and children 12 years of age and older with chronic graft-versus-host disease (chronic GvHD) after you have received at least 2 prior treatments (systemic therapy) and they did not work.

#### *Do not use if:*

- you are allergic (hypersensitive) to belumosudil or any of the other ingredients of this medicine.

#### *Talk to your Doctor or pharmacist*

Before taking belumosudil, tell your healthcare provider about all your medical conditions, including if you:

- have kidney or liver problems
- are pregnant or plan to become pregnant
- are breastfeeding or plan to breastfeed

#### *Other medicines and products*

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Belumosudil may affect the way other medicines work, and other medicines may affect the way belumosudil works.

Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.

#### *Pregnancy and/or breastfeeding*

If you are pregnant or plan to become pregnant, belumosudil can harm your unborn baby. If you are able to become pregnant, your healthcare provider will do a pregnancy test before starting treatment with belumosudil. Tell your healthcare provider if you become pregnant or think you may be pregnant during treatment with belumosudil.

Females who can become pregnant should use effective birth control during treatment with belumosudil and for at least 1 week after the last dose.

Males with female partners who can become pregnant should use effective birth control during treatment with belumosudil and for at least 1 week after the last dose.

It is not known if belumosudil passes into breast milk. Do not breastfeed during treatment with belumosudil and for at least 1 week after the last dose.

#### *Children and adolescents*

Belumosudil should not be used in children under the age of 12 years. It is not known if belumosudil is safe and effective in children less than 12 years old.

### Cautions on driving and using machinery

Be careful before you drive or use any machines or tools until you know how belumosudil affects you. Belumosudil is not expected to affect your ability to drive or operate machines.

### How to use belumosudil

- Take belumosudil exactly as your healthcare provider tells you to take it.
- Do not change your dose or stop taking belumosudil without first talking to your healthcare provider.
- Take belumosudil one time a day with a meal, unless instructed differently from your healthcare provider.
- Take belumosudil at about the same time each day.
- Swallow belumosudil tablets whole with a glass of water.
- Do not cut, crush, or chew belumosudil tablets.
- Your healthcare provider will do blood tests to check your liver at least 1 time a month during treatment with belumosudil.
- If you miss a dose of belumosudil, take it as soon as you remember on the same day. Take your next dose of belumosudil at your regular time on the next day. Do not take extra doses of belumosudil to make up for a missed dose.
- If you take too much belumosudil, call your healthcare provider or go to the nearest hospital emergency room right away.

### Side effects

The most common side effects of belumosudil include:

- tiredness or weakness
- diarrhea
- infections
- nausea
- shortness of breath
- cough
- swelling
- high blood pressure
- headache
- muscle or bone pain
- stomach (abdominal) pain

Your healthcare provider may change your dose of belumosudil, temporarily stop, or permanently stop treatment with belumosudil if you have certain side effects.

These are not all the possible side effects of belumosudil.

Call your doctor for medical advice about side effects.

### How to store belumosudil

Store belumosudil at room temperature between 68°F to 77°F (20°C to 25°C).

Keep belumosudil in its original container. The belumosudil bottle contains a desiccant packet to help keep your tablets dry (protect from moisture). Keep the desiccant in the bottle.

Tightly close the belumosudil bottle after you take your dose.

Keep belumosudil and all medicines out of the reach of children.

### Ingredients/Composition

Active ingredient: belumosudil mesylate Inactive ingredients:

- Tablet core: microcrystalline cellulose, hypromellose, croscarmellose sodium, colloidal silicon dioxide, and magnesium stearate.
- Tablet coating: polyvinyl alcohol, polyethylene glycol, talc, titanium dioxide and yellow iron oxide.

## **10 Details of manufacturer**

1. Manufacture, Packaging (primary and secondary), Labeling, Release testing, Stability testing

### **UPM PHARMACEUTICALS**

501 Fifth Street  
BRISTOL, TN 37620  
United States

2. Labeling and Secondary Packaging of commercial batches

### **PHARMA PACKAGING SOLUTIONS, LLC dba Tjoapack, LLC**

341 JD Yarnell Industrial Parkway  
CLINTON, TN 37716  
United States

## **11 Imported and Marketed by:**

Sanofi Healthcare India Private Limited, Gala No. 4, Ground Floor, Building No. B1, Citylink Warehousing Complex, S No.121/10/A, 121/10/B & 69, NH3, Vadape. Tal: Bhiwandi – 16 (Thane Z5) Pin: 421302

## **12 Details of permission or license number with date**

IMP-ND-49/2024 dated Nov 2024

## **13 Date of revision**

**Aug 2025**

**Ref: CCDS V5 dated 03-Jul-2025**